Almirall announces receipt of 15 million dollars (€10.5 million) from Forest Laboratories in connection with phase III development of aclidinium bromide
Barcelona, 23 September 2008.- Almirall, the international pharmaceutical company based in Spain, announces that is has received 15 million dollars (€ 10.5 million) from Forest Laboratories in connection with its phase III development of aclidinium bromide, an antimuscarinic for the treatment of COPD (Chronic Obstructive Pulmonary Disease).
This amount, to be entered this quarter, forms part of the co-development and marketing agreement between Almirall and Forest Laboratories for the product.
Almirall
Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general.
Almirall is currently present in over 70 countries with direct presence in
More information:
Ketchum/SEIS
Sonia San Segundo/Patricia Mansilla
Tel.: 91 788 32 00